Alzheimer’s Disease Blood Test
There is exciting news in the field of Alzheimer’s disease (AD) research with the advent of a new blood test. This Alzheimer’s disease blood test can determine the presence of a key marker, brain amyloidosis. AD is associated with the buildup of amyloid proteins in the brain, as well as other blood proteins. Early detection of the disease in Paramus can have implications in terms of benefiting from any current and new treatments, joining research trials underway and taking advantage earlier of any support services available.
Available Tests
The blood test can be administered after a clinical examination uncovers symptoms of Alzheimer’s disease including cognitive impairment such as dementia. Fortunately, this new blood test is safe, affordable and easy to administer in a variety of settings. Currently, we can only do definitive tests for AD post mortem. There are major drawbacks to other tests. The first method of extracting cerebrospinal fluid requires an invasive spinal tap. Furthermore, it carries the risk of nerve damage. The second is a PET scan testing for amyloids in the brain. This test exposes the patient to radiation. Another disadvantage is that it is not usually covered by insurance. However, few centers have the technology. Autopsies can reveal brain beta amyloid proteins in the brain, a hallmark sign of AD. Obviously, this has no benefit to the sufferer at that time.
Benefits of the Blood Test
Eli Lilly developed a blood test that could detect Alzheimer’s disease through elevated levels of p-tau217 at an accuracy rate between 89-98%. This rate is similar to that of a PET scan and cerebrospinal fluid tests. This rate is higher than other known blood tests. People who have a gene for Alzheimer’s disease had higher levels of p-tau217 that could be detected 20 years before any symptoms appeared.
This new test also has the benefit of reducing the stress of not knowing for the patient and their loved ones. Moreover, an important byproduct of the test is enhancing the integrity of research. Also, this tests ensures that only true AD patients are included in any treatment trials. These trials currently have an error rate of about 25% of non-AD patient inclusion.
David York Agency Home Healthcare Helps Seniors in Paramus
Receiving a diagnosis of Alzheimer’s disease is naturally extremely stressful to all concerned. Sadly, anticipating and planning for the eventual outcome of the disease is not easy. Please remember that David York Home Healthcare Agency can help. When home healthcare becomes necessary, David York Agency provides homecare services for the elderly and infirm in their home. We would be happy to discuss your case with you.
At David York Home Healthcare Agency, extraordinary service is what sets us apart from other companies who provide in home health care services. Whatever your care needs, we are there for you, always striving to exceed your expectations. For more information about David York Agency’s qualified, compassionate caregivers, contact us at (908) 373-5300. A free phone consultation can help you determine what services would meet your needs. We aim to provide you and your loved one with the assistance they need. If you’d like to hear more from us, please like us on Facebook or follow us on Twitter or LinkedIn.
For more helpful tips and information, contact us today.
